| The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. | |
| | |
MedLine Citation:
|
PMID: 14745084 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized, blinded, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and acute symptomatic effects of CEP-1347 in 30 patients with Parkinson's disease (PD). In this short-term study, CEP-1347 was safe and well tolerated. It had no acute effect on parkinsonian symptoms or levodopa pharmacokinetics, making it well suited for larger and longer studies of its potential to modify the course of PD. |
| | |
Authors:
|
|
Related Documents
:
|
6402914 - Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial. 23014254 - Descriptive analysis of resistance exercise and metabolic syndrome. 1281624 - Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in ca... 6214914 - Double-blind comparison of diltiazem and placebo in the treatment of exercise-inducible... 1483444 - Glucocorticoid response to exercise as measured by serum and salivary cortisol. 6369064 - Metabolic bases of excess post-exercise oxygen consumption: a review. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Neurology Volume: 62 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2004-01-27 Completed Date: 2005-01-14 Revised Date: 2008-06-28 |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 330-2 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antiparkinson Agents / adverse effects, blood, pharmacokinetics, therapeutic use* Area Under Curve Carbazoles / adverse effects, blood, pharmacokinetics, therapeutic use* Diarrhea / chemically induced Double-Blind Method Female Humans Indoles / adverse effects, blood, pharmacokinetics, therapeutic use* Levodopa / therapeutic use Male Middle Aged Parkinson Disease / blood, drug therapy*, enzymology Protein Kinase Inhibitors / adverse effects, blood, pharmacokinetics, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antiparkinson Agents; 0/Carbazoles; 0/Indoles; 0/Levodopa; 0/Protein Kinase Inhibitors; 156177-65-0/3,9-bis((ethylthio)methyl)-K-252a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Spinocerebellar ataxia type 5: clinical and molecular genetic features of a German kindred.
Next Document: Effects of nitric oxide on proprioceptive signaling.